Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 5/20 | 0.34 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20076318 | 0.92 | MAPT (0.47) | MAPTKMT2ANAAACES2CES1 | |
| SCHEMBL8895814 | 0.90 | MAPT (0.45) | MAPTKMT2ACES2CES1ALDH1A1 | |
| SCHEMBL3280838 | 0.83 | FFAR1 (0.38) | MAPTKMT2AFFAR1CPT2TDP1 | |
| SCHEMBL13387743 | 0.83 | CYP4F2 (0.38) | MAPTKMT2AALDH1A1FFAR1CPT2 | |
| SCHEMBL8899335 | 0.82 | KMT2A (0.47) | MAPTKMT2ACES2CES1ALDH1A1 | |
| SCHEMBL8898144 | 0.82 | KMT2A (0.52) | MAPTKMT2ACES2CES1ALDH1A1 | |
| SCHEMBL3279852 | 0.81 | FFAR1 (0.37) | MAPTKMT2AFFAR1CPT2TDP1 | |
| SCHEMBL94904 | 0.80 | — | — | |
| SCHEMBL15183711 | 0.79 | MAPT (0.32) | MAPTKMT2A | |
| SCHEMBL9385485 | 0.78 | CES1 (0.50) | MAPTKMT2ANAAACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | MAPT 1415/4885KMT2A 4492/4885NAAA 4715/4885 |
| US-20180105558-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | MAPT 1874/4885KMT2A 4495/4885NAAA 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.